Asian Liver Transplant Network Clinical Guidelines on Immunosuppression in Liver Transplantation

Poh Seng Tan; Mark D. Muthiah; Tsingyi Koh; Yee Leong Teoh; Albert Chan; Alfred Kow; Qishi Zheng; Choon Hyuck David Kwon; Guan Huei Lee; Cosmas Rinaldi A. Lesmana; Vanessa De Villa; James Fung; Kieron Lim

doi:10.1097/TP.0000000000002532

Asian Liver Transplant Network Clinical Guidelines on Immunosuppression in Liver Transplantation

Poh Seng Tan, Mark D. Muthiah, Tsingyi Koh, Yee Leong Teoh, Albert Chan, Alfred Kow, Qishi Zheng, Choon Hyuck David Kwon, Guan Huei Lee, Cosmas Rinaldi A. Lesmana, Vanessa De Villa, James Fung, Kieron Lim

Department of Internal Medicine

Research output: Contribution to journal › Review article › peer-review

34 Citations (Scopus)

Abstract

Most management guidelines and much of the available clinical trial evidence for immunosuppressants in liver transplantation (LT) pertain to Western practice. While evidence from Western studies may not translate to Asian settings, there is a paucity of Asian randomized controlled trials of immunosuppression in liver recipients. Nonetheless, there are notable differences in the indications and procedures for LT between Western and Asian settings. The Asian Liver Transplant Network held its inaugural meeting in Singapore in November 2016 and aimed to provide an Asian perspective on aspects of immunosuppression following LT. Because of their importance to outcome following LT, the meeting focused on (1) reducing the impact of renal toxicity, (2) hepatocellular carcinoma recurrence, and (3) nonadherence with immunosuppressant therapy.

Original language	English
Pages (from-to)	470-480
Number of pages	11
Journal	Transplantation
Volume	103
Issue number	3
DOIs	https://doi.org/10.1097/TP.0000000000002532
Publication status	Published - 1 Mar 2019

Access to Document

10.1097/TP.0000000000002532

Cite this

@article{7117a488f4de4dbb8e5337c68279e0c0,

title = "Asian Liver Transplant Network Clinical Guidelines on Immunosuppression in Liver Transplantation",

abstract = "Most management guidelines and much of the available clinical trial evidence for immunosuppressants in liver transplantation (LT) pertain to Western practice. While evidence from Western studies may not translate to Asian settings, there is a paucity of Asian randomized controlled trials of immunosuppression in liver recipients. Nonetheless, there are notable differences in the indications and procedures for LT between Western and Asian settings. The Asian Liver Transplant Network held its inaugural meeting in Singapore in November 2016 and aimed to provide an Asian perspective on aspects of immunosuppression following LT. Because of their importance to outcome following LT, the meeting focused on (1) reducing the impact of renal toxicity, (2) hepatocellular carcinoma recurrence, and (3) nonadherence with immunosuppressant therapy.",

author = "Tan, {Poh Seng} and Muthiah, {Mark D.} and Tsingyi Koh and Teoh, {Yee Leong} and Albert Chan and Alfred Kow and Qishi Zheng and Kwon, {Choon Hyuck David} and Lee, {Guan Huei} and Lesmana, {Cosmas Rinaldi A.} and {De Villa}, Vanessa and James Fung and Kieron Lim",

note = "Publisher Copyright: {\textcopyright} 2019 Wolters Kluwer Health, Inc.",

year = "2019",

month = mar,

day = "1",

doi = "10.1097/TP.0000000000002532",

language = "English",

volume = "103",

pages = "470--480",

journal = "Transplantation",

issn = "0041-1337",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Asian Liver Transplant Network Clinical Guidelines on Immunosuppression in Liver Transplantation

AU - Tan, Poh Seng

AU - Muthiah, Mark D.

AU - Koh, Tsingyi

AU - Teoh, Yee Leong

AU - Chan, Albert

AU - Kow, Alfred

AU - Zheng, Qishi

AU - Kwon, Choon Hyuck David

AU - Lee, Guan Huei

AU - Lesmana, Cosmas Rinaldi A.

AU - De Villa, Vanessa

AU - Fung, James

AU - Lim, Kieron

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Most management guidelines and much of the available clinical trial evidence for immunosuppressants in liver transplantation (LT) pertain to Western practice. While evidence from Western studies may not translate to Asian settings, there is a paucity of Asian randomized controlled trials of immunosuppression in liver recipients. Nonetheless, there are notable differences in the indications and procedures for LT between Western and Asian settings. The Asian Liver Transplant Network held its inaugural meeting in Singapore in November 2016 and aimed to provide an Asian perspective on aspects of immunosuppression following LT. Because of their importance to outcome following LT, the meeting focused on (1) reducing the impact of renal toxicity, (2) hepatocellular carcinoma recurrence, and (3) nonadherence with immunosuppressant therapy.

AB - Most management guidelines and much of the available clinical trial evidence for immunosuppressants in liver transplantation (LT) pertain to Western practice. While evidence from Western studies may not translate to Asian settings, there is a paucity of Asian randomized controlled trials of immunosuppression in liver recipients. Nonetheless, there are notable differences in the indications and procedures for LT between Western and Asian settings. The Asian Liver Transplant Network held its inaugural meeting in Singapore in November 2016 and aimed to provide an Asian perspective on aspects of immunosuppression following LT. Because of their importance to outcome following LT, the meeting focused on (1) reducing the impact of renal toxicity, (2) hepatocellular carcinoma recurrence, and (3) nonadherence with immunosuppressant therapy.

UR - http://www.scopus.com/inward/record.url?scp=85062098339&partnerID=8YFLogxK

U2 - 10.1097/TP.0000000000002532

DO - 10.1097/TP.0000000000002532

M3 - Review article

C2 - 30422953

AN - SCOPUS:85062098339

SN - 0041-1337

VL - 103

SP - 470

EP - 480

JO - Transplantation

JF - Transplantation

IS - 3

ER -

Asian Liver Transplant Network Clinical Guidelines on Immunosuppression in Liver Transplantation

Abstract

Access to Document

Other files and links

Fingerprint

Cite this